Cantor Fitzgerald analyst Charles C. Duncan reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE